Gaurav D. Gaiha

Gaurav D. Gaiha, MD, DPhil

Principal Investigator


Group Leader

Ragon Institute of MGH, MIT and Harvard

Contact


(857)268-7016

862

T cells, Vaccines, & Immune Control

Research Overview

The overarching goal of the Gaiha Lab is to translate insights from successful human T cell responses into efficacious T cell-based vaccines for infectious disease and cancer.

The Gaiha Lab is working to establish a T cell vaccine platform that incorporates target epitope identification, HLA-epitope stability assessments, T cell immunogen design, viral vector production, and iterative testing in small animal models. We work with a structure-based network analysis technology, which integrates network theory with protein structure data to define topologically important and mutationally constrained regions of viral proteins. We utilized this approach to identify key targets of CD8+ T cells in individuals who spontaneously control HIV (Gaiha et al., Science 2019) and, more recently, identify mutation-resistant epitopes SARS-CoV-2 (Nathan, Rossin, et al., 2021). The overarching goal is to integrate these technologies towards developing prophylactic and therapeutic vaccines for HIV and SARS-CoV-2 and ultimately for broad translation to infectious diseases and cancer.  

Recognition and Media

Dr. Gaiha has been awarded the NIAID New Innovators DP2 Award and has been recognized as a Gilead HIV Research Scholar. He has also been named a Burroughs Wellcome Career Award for Medical Scientists and has been awarded the CHAVD (NIH) and CAVD (Gates Foundation) New Investigator Awards.

About

Dr. Gaiha received his D.Phil in Biochemistry from Oxford University as a Clarendon Scholar and his MD magna cum laude from the Health Sciences and Technology (HST) program at Harvard Medical School and MIT. He trained in Internal Medicine and Gastroenterology at MGH before completing his post-doctoral research fellowship at the Ragon Institute.

Selected Publications

Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses

A. Nathan, E. J. Rossin, C. Kaseke, R. J. Park, A. Khatri, D. Koundakjian, J. M. Urbach, N. K. Singh, A. Bashirova, R. Tano-Menka, F. Senjobe, M. T. Waring, A. Piechocka-Trocha, W. F. Garcia-Beltran, A. J. Iafrate, V. Naranbhai, M. Carrington, B. D. Walker, G. D. Gaiha.

Cell (2021).

HLA class-I-peptide stability mediates CD8+ T cell immunodominance hierarchies and facilitates HLA-associated immune control of HIV

C. Kaseke, R. J. Park, N. K. Singh, D. Koundakjian, A. Bashirova, W. F. Garcia Beltran, O. C. Takou Mbah, J. Ma, F. Senjobe, J. M. Urbach, A. Nathan, E. J. Rossin, R. Tano-Menka, A. Khatri, A. Piechocka-Trocha, M. T. Waring, M. E. Birnbaum, B. M. Baker, M. Carrington, B. D. Walker, G. D. Gaiha.

Cell Rep. 36, (2021).

Structural topology defines protective CD8+ T cell epitopes in the HIV proteome

Gaiha et al.

Science, 2019. 364, 480-484

Structure-guided T cell vaccine design for SARS-CoV-2 with broad coverage of circulating variants and sarbecoviruses

Nathan, Rossin et al.

2021. Under Revision

HLA class I-peptide stability mediates CD8+ T cell immunodominance hierarchies and facilitates HLA-associated immune control of HIV

Kaseke et al.

2021. Under Revision

Lab Team

Matthew Getz

Research Fellow

Zezhou Zhao

Graduate Student

Explore More

Culture

Our people are our greatest asset. We are committed to creating a supportive and inclusive environment that is welcoming for all.

READ MORE

Leadership: Faculty

The Ragon’s faculty includes many of the world’s most creative scientists, engineers, and clinicians.

READ MORE

Research

The Ragon’s research creates knowledge from our collaborative, cross-disciplinary approach, breaking down the silos of academia.

READ MORE